Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate

被引：28
|
作者：
Rousselot, P [1 ]
Larghero, J
Raffoux, E
Calvo, F
Tulliez, M
Giraudier, S
Rybojad, M
机构：
[1] Hop St Louis, Serv Clin Malad Sang, Paris, France
[2] Hop St Louis, Ctr Invest Clin, Paris, France
[3] Hop Henri Mondor, Hematol Lab, F-94010 Creteil, France
[4] Hop St Louis, Serv Dermatol, F-75475 Paris, France
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2003年 / 120卷 / 06期
关键词：
imatinib mesylate; c-Kit; chronic myelogenous leukaemia; photosensitivity; depigmentation;
D O I：
10.1046/j.1365-2141.2003.04208_3.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1091 / 1092
页数：2
相关论文
共 50 条
  • [1] Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate
    Isobe, Y.
    Sugimoto, K.
    Masuda, A.
    Hamano, Y.
    Oshimi, K.
    INTERNAL MEDICINE JOURNAL, 2009, 39 (06) : 408 - 411
  • [2] Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia
    Kim, Dong-Wook
    Tan, Eugene Y.
    Jin, Yu
    Park, Sahee
    Hayes, Michael
    Demirhan, Eren
    Schran, Horst
    Wang, Yanfeng
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (02) : 199 - 206
  • [3] Early imatinib mesylate-induced hepatotoxicity in chronic myelogenous leukaemia
    Kong, Jee Hyun
    Yoo, Seung-Hyun
    Lee, Kyoung Eun
    Nam, Seung Hyun
    Kwon, Jung Mi
    Lee, Sang Min
    Chang, Hye Jung
    Choi, Moon Young
    Cho, Min Sun
    Mun, Yeung-Chul
    Nam, Eunmi
    Lee, Soon Nam
    Seong, Chu-Myong
    ACTA HAEMATOLOGICA, 2007, 118 (04) : 205 - 208
  • [4] Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment
    Oku, Eijiro
    Imamura, Rie
    Nagata, Shuichiro
    Takata, Yuka
    Seki, Ritsuko
    Otsubo, Korenori
    Hashiguchi, Michitoshi
    Osaki, Koichi
    Yakushiji, Kazuaki
    Yoshimoto, Kohji
    Ogata, Hideaki
    Sata, Michio
    Okamura, Takashi
    ACTA HAEMATOLOGICA, 2007, 117 (04) : 191 - 196
  • [5] Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    Cortes, J
    Talpaz, M
    O'Brien, S
    Jones, D
    Luthra, R
    Shan, J
    Giles, F
    Faderl, S
    Verstovsek, S
    Garcia-Manero, G
    Rios, MB
    Kantarjian, H
    CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3425 - 3432
  • [6] Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate
    Anthony, Navin
    Shanks, James
    Terebelo, Howard
    LEUKEMIA RESEARCH, 2010, 34 (09) : 1250 - 1251
  • [7] Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib
    Ugurel, S
    Lahaye, T
    Hildenbrand, R
    Glorer, E
    Reiter, A
    Hochhaus, A
    Schadendorf, D
    Goerdt, S
    BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (03) : 678 - 679
  • [8] Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome
    El-Zimaity, MMT
    Kantarjian, H
    Talpaz, M
    O'Brien, S
    Giles, F
    Garcia-Manero, G
    Verstovsek, S
    Thomas, D
    Ferrajoli, A
    Hayes, K
    Bekele, BN
    Zhou, X
    Rios, MB
    Glassman, AB
    Cortes, JE
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (02) : 187 - 195
  • [9] Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    Hwang, Yu-Yan
    Tse, Eric
    So, Jason C. C.
    Wan, Thomas S. K.
    Kwong, Yok-Lam
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (05) : 302 - 305
  • [10] Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML)
    Thakral, Beenu
    Higa, Bryce
    Venkataraman, Girish
    Velankar, Milind M.
    PATHOLOGY, 2012, 44 (01) : 59 - 59
12345